Wire · regulatory
Karyopharm to submit sNDA to US FDA in Aug 2026 seeking accelerated approval of ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 August 2026 · Fusion42 review
Karyopharm plans to submit a supplemental New Drug Application (sNDA) to the US FDA in August 2026 seeking accelerated approval for selinexor in combination with ruxolitinib to treat myelofibrosis, supported by significant clinical trial data including spleen volume reduction and overall survival signals.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 31 Jul 2026 and 1 Aug 2026.
◆ ◆ The Wire takeaway
The US regulatory path is opening for a new myelofibrosis treatment combining selinexor and ruxolitinib. If you develop therapies for blood cancers, this approval route could unblock market entry or shift competitive dynamics.
◆ Coverage
2 sources · first reported 31 Jul 2026 · latest 1 Aug 2026
◆ Related on Wire
◆ Topics